The ROE as of September 2024 (TTM) for 9 Meters Biopharma, Inc. (NMTR) is -1215.30%

According to 9 Meters Biopharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -1215.30%. This represents a change of 1.06% compared to the average of -104.58% of the last 4 quarters.

9 Meters Biopharma, Inc. (NMTR) Historical ROE (quarterly & annually)

How has NMTR ROE performed in the past?

The mean historical ROE of 9 Meters Biopharma, Inc. over the last ten years is -5.98%. The current -1215.30% ROE has changed 20.21% with respect to the historical average. Over the past ten years (40 quarters), NMTR's ROE was at its highest in in the June 2017 quarter at 769.01%. The ROE was at its lowest in in the June 2020 quarter at -1453.97%.

9 Meters Biopharma, Inc. (NMTR) ROE by Quarter and Year

Discovering the peaks and valleys of 9 Meters Biopharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

9 Meters Biopharma, Inc. (NMTR) Average ROE

How has NMTR ROE performed in the past?

The current ROE of 9 Meters Biopharma, Inc. (NMTR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

9 Meters Biopharma, Inc. (NMTR) ROE vs. Peers

How is NMTR’s ROE compared to its peers?

9 Meters Biopharma, Inc.’s ROE is greater than Mereo BioPharma Group plc (-63.39%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Inozyme Pharma, Inc. (-68.93%), less than Galera Therapeutics, Inc. (21.95%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Artelo Biosciences, Inc. (-37.69%), greater than Histogen Inc. (-108.33%), greater than Curis, Inc. (-328.39%), greater than Timber Pharmaceuticals, Inc. (-520.78%), less than Kineta, Inc. (934.78%), greater than Candel Therapeutics, Inc. (-629.29%), less than MiNK Therapeutics, Inc. (99.78%), greater than Forte Biosciences, Inc. (-117.85%), greater than AlloVir, Inc. (-96.48%), less than ZIVO Bioscience, Inc. (673.84%), greater than RenovoRx, Inc. (-403.38%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Ikena Oncology, Inc. (-42.81%), less than Catalyst Biosciences, Inc. (1.20%), less than MEI Pharma, Inc. (48.32%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than Vincerx Pharma, Inc. (-276.65%), greater than Avenue Therapeutics, Inc. (-749.10%),

Build a custom stock screener for 9 Meters Biopharma, Inc. (NMTR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 9 Meters Biopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

9 Meters Biopharma, Inc. (NMTR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like 9 Meters Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.